Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter
Gaithersburg, Maryland–(Newsfile Corp. – August 28, 2026) – Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (the “Company” or “Shuttle”), today announced that the Company is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 with the Securities and Exchange Commission by the required due date.
The Company intends to file the Form 10-Q as soon as practicable.
The Company is required to submit a plan, by October 27, 2026, which outlines the steps the Company expects to take to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq can grant an exception of up to 180 calendar days from the due date of the Form 10-Q, or until February 22, 2027, to regain compliance. However, there can be no assurance that Nasdaq will accept the Company’s plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq.
The Nasdaq Notice has no immediate effect on the listing or trading of the Company’s common stock, though Nasdaq makes available to investors a list of non-compliant companies, which will include Shuttle beginning on approximately September 4, 2026. As part of this process, an indicator reflecting the Company’s non-compliance will be broadcast over Nasdaq’s market data dissemination network and will also be made available to third party market data providers. If the Company fails to timely regain compliance, the Company’s common stock will be subject to delisting from Nasdaq.
-Ends-
About Shuttle Pharmaceuticals
Shuttle (NASDAQ: SHPH) owns a pharmaceutical software AI driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.
United Dogecoin, a wholly-owned subsidiary of Shuttle, is a start-up digital infrastructure company focused on the development, ownership, and operation of large-scale computing infrastructure supporting blockchain networks, artificial intelligence, and high-performance computing workloads. It is seeking to build an energy-first digital infrastructure platform designed to deploy computing capacity across multiple end markets as demand evolves.
